Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2026)

Crinetics Pharmaceuticals has reported Research & Development for 10 years, with the latest figure at $100.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 31.27% year-over-year to $100.1 million; the trailing twelve-month figure through Mar 2026 stood at $355.9 million (up 35.29% YoY), and the FY2025 full-year result was $332.1 million, up 38.27% from the prior year.
• Research & Development for Q1 2026 stood at $100.1 million, up from $85.1 million in the prior quarter.
• The five-year high for Research & Development was $100.1 million in Q1 2026, with the low at $28.3 million in Q1 2022.
• Average Research & Development over 5 years is $57.1 million, with a median of $53.3 million recorded in 2024.
• Year-over-year, Research & Development soared 61.05% in 2022 and rose 23.17% in 2023.
• Tracing CRNX's Research & Development over 5 years: stood at $37.0 million in 2022, then advanced by 23.22% to $45.6 million in 2023, then jumped by 46.04% to $66.6 million in 2024, then gained by 27.77% to $85.1 million in 2025, then grew by 17.67% to $100.1 million in 2026.
• The last three Research & Development figures came in at $100.1 million (Q1 2026), $85.1 million (Q4 2025), and $90.5 million (Q3 2025), per Business Quant data.

Peer Comparison